Palliative Thoracic ImmunoRT

Official Title

Evaluation of Toxicities With Thoracic Radiation Therapy and Immune Checkpoint Inhibition in Non-small Cell Lung Cancer


The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiation therapy and treated with a standard dose prescription of 30 Gy in 10 fractions.

Trial Description

Primary Outcome:

  • Rate of Radiation related toxicities
  • Patient Report Outcome
  • Patient experience and anxiety related to Quality of Life
Secondary Outcome:
  • Rate of Survival
  • Rate of Survival
  • Rate of Disease Recurrence

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society